Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma

Abstract Purpose Ramucirumab was shown to be effective as a second-line treatment after sorafenib in patients with advanced hepatocellular carcinoma (HCC) with alpha-fetoprotein levels > 400 ng/mL in a worldwide phase 3 trial. Ramucirumab is used in patients pretreated with various systemic therapie...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Naoya Kanogawa, Sadahisa Ogasawara, Susumu Maruta, Yotaro Iino, Masamichi Obu, Takamasa Ishino, Keita Ogawa, Sae Yumita, Terunao Iwanaga, Hidemi Unozawa, Miyuki Nakagawa, Kisako Fujiwara, Takafumi Sakuma, Naoto Fujita, Ryuta Kojima, Hiroaki Kanzaki, Keisuke Koroki, Kazufumi Kobayashi, Masanori Inoue, Soichiro Kiyono, Masato Nakamura, Takayuki Kondo, Tomoko Saito, Ryo Nakagawa, Shingo Nakamoto, Ryosuke Muroyama, Tetsuhiro Chiba, Ei Itobayashi, Yoshihiro Koma, Ryosaku Azemoto, Jun Kato, Naoya Kato
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2023-03-01
coleção:	BMC Gastroenterology
Assuntos:	Hepatocellular carcinoma Ramucirumab Late-line REACH-2
Acesso em linha:	https://doi.org/10.1186/s12876-023-02674-x
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!